Belgian value-added medicines specialist Hyloris Pharmaceuticals has struck a deal worth up to €4.3m ($5.2m) with Purna Female Healthcare to develop an innovative “dual mode-of-action” treatment for severe and recurrent vulvovaginal candidiasis that combines miconazole and domiphen bromide.
Purna Female Healthcare is a spin-off founded by Purna Pharmaceuticals and Creafund as a “special purpose vehicle founded to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?